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ABSTRACT
Hepatocellular carcinoma (HCC) is a lethal malignancy with high mortality and 
poor prognosis. Oncogenic transcription factor Late SV40 Factor (LSF) plays an 
important role in promoting HCC. A small molecule inhibitor of LSF, Factor Quinolinone 
Inhibitor 1 (FQI1), significantly inhibited human HCC xenografts in nude mice 
without harming normal cells. Here we evaluated the efficacy of FQI1 and another 
inhibitor, FQI2, in inhibiting endogenous hepatocarcinogenesis. HCC was induced in 
a transgenic mouse with hepatocyte-specific overexpression of c-myc (Alb/c-myc) 
by injecting N-nitrosodiethylamine (DEN) followed by FQI1 or FQI2 treatment after 
tumor development. LSF inhibitors markedly decreased tumor burden in Alb/c-myc 
mice with a corresponding decrease in proliferation and angiogenesis. Interestingly, 
in vitro treatment of human HCC cells with LSF inhibitors resulted in mitotic arrest 
with an accompanying increase in CyclinB1. Inhibition of CyclinB1 induction by 
Cycloheximide or CDK1 activity by Roscovitine significantly prevented FQI-induced 
mitotic arrest. A significant induction of apoptosis was also observed upon treatment 
with FQI. These effects of LSF inhibition, mitotic arrest and induction of apoptosis by 
FQI1s provide multiple avenues by which these inhibitors eliminate HCC cells. LSF 
inhibitors might be highly potent and effective therapeutics for HCC either alone or 
in combination with currently existing therapies.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the five 
most common malignancies and the third leading cause 
of cancer related deaths worldwide [1]. Despite a decline 
in overall cancer incidence, there is a steady increase 
in the incidence of HCC, especially in the US [2]. This 
problem is compounded by the fact that HCC is a disease 
with very poor prognosis with only 10% of patients 
having 5 year mean survival rate using currently available 
treatments [3]. The only FDA-approved drug, sorafenib, 
for non-resectable HCC provides a survival benefit of 
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only 2.8 months [4]. As such there is an urgent need for 
developing new molecular targeted therapy for HCC.
We previously identified overexpression of the 
transcription factor Late SV40 factor (LSF) in ~90% of 
human HCC patients which could be significantly correlated 
with the stages of the disease and ‘gain-of-function’ and 
‘loss-of-function’ studies established the significance of LSF 
in promoting hepatocarcinogenesis [5–9]. Furthermore, LSF 
positively regulates all the major hallmarks of cancer in HCC. 
First, LSF transcriptionally regulates osteoponin (OPN) in 
HCC, which activates c-Met signaling, thereby mediating the 
oncogenic function of LSF and promoting metastasis [5, 6]. 
Second, we identified matrix metalloproteinase-9 (MMP-9) 
as a target gene of LSF, important for mediating LSF-induced 
angiogenesis [8]. Third, LSF overexpression can contribute 
to chemoresistance [7], since LSF transcriptionally regulates 
expression of thymidylate synthase [10], a target of the 
chemotherapeutic agent 5-fluorouracil [7]. Finally, nuclear 
translocation of LSF upon overexpression of Snail can lead 
to transcriptional upregulation of fibronectin expression, 
contributing to induction of the epithelial-mesenchymal 
transition (EMT) [11].
We previously identified Factor Quinolinone 
Inhibitors (FQIs) as specific inhibitors of LSF DNA-
binding and of LSF transcriptional activation [12]. The 
prototype, FQI1, markedly inhibited proliferation and 
induced apoptosis of human HCC cells at low micromolar 
doses, without causing toxicity to normal immortal human 
hepatocytes or primary mouse hepatocytes [12]. In a 
subcutaneous xenograft model of human HCC in athymic 
nude mice, FQI1 profoundly inhibited tumor growth 
without causing toxicity to any other organs [12]. These 
intriguing results suggested that FQIs might be effective 
therapeutics for HCC, although requiring further stringent 
evaluation.
We now demonstrate therapeutic efficacy of FQI1 
and a related compound FQI2 in an endogenous mouse 
model of HCC. We also document that FQIs cause mitotic 
arrest and subsequent apoptosis. The lack of toxicity 
combined with the targeting of this well-documented 
vulnerability in cancer cells strongly support further 
evaluation of FQIs in a Phase I/II clinical trial.
RESULTS
Therapeutic efficacy of LSF inhibitors on 
endogenous HCC
Alb/c-myc mice spontaneously develop HCC 
and the kinetics of the hepatocarcinogenic process is 
significantly accelerated upon treatment with DEN [13]. 
The chemotherapeutic efficacy of LSF inhibitors was 
evaluated in Alb/c-myc mice harboring DEN-induced 
liver tumors. The animals, treated with FQI1 and FQI2, 
demonstrated marked decrease in tumor nodules (2 mm 
or less in size) when compared to control (vehicle treated) 
animals (Figure 1A upper panel). Histological examination 
of the liver showed features of HCC in control animals 
while FQI1- and FQI2-treated animals maintained normal 
hepatic architecture (Figure 1A, lower panel). The liver 
weight (Figure 1B) and number of nodules (Figure 1C) in 
control mice were significantly higher than that in treated 
mice suggestive of decrease in tumor burden upon FQI 
treatment. Biochemically, the level of enzymes indicating 
liver damage, such as Aspartate Aminotransferase 
(AST), Alanine Aminotransferase (ALT) and Alkaline 
Phosphatase, showed significant decreases upon FQI 
treatment when compared to control (Figure 1D). 
Immunohistochemical analysis of tumors revealed 
significant increases in the HCC marker α-fetoprotein 
(AFP), proliferation marker proliferating cell nuclear 
antigen (PCNA), LSF target gene osteopontin (OPN) and 
thymidylate synthase (TS) and angiogenesis marker CD31 
only in control animals but not in FQI1- or FQI2-treated 
animals (Figure 1E). Increased TUNNEL positive cells 
(apoptotic cells) were observed in FQI1- or FQI2-treated 
groups when compared to control animals (Figure 1F). No 
obvious signs of toxicity, such as weight loss or changes in 
behavior, feeding or grooming, were observed upon FQI1 
or FQI2 treatment suggesting that these agents might be 
potent and non-toxic HCC therapeutics.
LSF inhibitors decrease proliferation of human 
HCC cells and induce G2/M cell cycle arrest
To obtain better insights into the mechanism of 
action of FQI1 and FQI2, we performed a comparative 
analysis of the effects of these two agents on human HCC 
cells, QGY-7703 and Huh7. Cell proliferation analysis 
by standard MTT assay showed that both FQI1 and FQI2 
markedly decreased cell growth in a dose- and time-
dependent manner (Figure 2A). QGY-7703 cells showed 
~90% reduction in cell growth by 48 hours while the 
kinetics of killing in Huh7 cells was relatively slower. As 
such for most of the studies we used 24 h treatment for 
QGY-7703 cells and 48 h treatment for Huh7 cells.
LSF transcriptionally regulates thymidylate synthase 
and we previously demonstrated that inhibition of LSF in 
multiple cell types by expression of a dominant negative 
LSF mutant induces a G1/S block or apoptosis in S phase 
[10, 14], and in QGY-7703 cells induces cell cycle delay 
in S phase [15]. To our surprise, treatment of serum-
starved and released QGY-7703 and Huh7 cells with 2 μM 
FQI1 or FQI2 resulted in potent cell cycle arrest in G
2
/M 
phase along with an increase in sub-G1 peak suggestive of 
apoptosis (Figure 2B). Quantification of distribution of cells 
in each phase of the cell cycle is provided in Supplementary 
Figure S1. FQI1 treatment showed an increased sub-G1 
peak, compared to FQI2 treatment, in QGY-7703 cells, 
prompting us to probe into this phenomenon in detail. Since 
FQI2 is more potent than FQI1 in inhibiting LSF activity 
and in inhibiting cell proliferation (10), we synchronized 
QGY-7703 cells at the G1/S boundary by double thymidine 
block and released the cells at 0 h in the presence of FQI1 
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at 2 μM or 5 μM concentration. Upon analysis of cellular 
DNA content, vehicle-treated cells re-entered cell cycle in 
G1 phase by 10 h after release, while FQI1-treated cells, 
with both 2 and 5 μM concentrations, were arrested at G
2
/M 
phase (Figure 2C). Interestingly, at 17 h post-treatment, 
cells treated with 5 μM FQI1 maintained G
2
/M arrest 
while cells treated with 2 μM FQI1 showed an increase in 
sub-G1 peak. These findings suggest that dosage of the drug 
determines cell fate and that FQI2 exerts a more potent cell 
cycle inhibitory effect than FQI1, similar to its more potent 
LSF inhibitory effect.
Induction of CyclinB1 upon FQI1 and FQI2 
treatment
We checked the expression pattern of CyclinB1, 
CDK1 and CDC25c, which function at the G
2
/M transition, 
upon FQI1 and FQI2 treatment. CyclinB1 level was 
Figure 1: LSF inhibitors abrogate endogenous HCC in Alb/c-myc mice. Protocols for induction of HCC and treatment of animals 
are described in Materials and Methods. A. Upper panel, representative photographs of livers of DMSO-, FQI1- and FQI2-treated mice 
at the end of the experiment. Lower panel, representative H & E stained liver sections of the indicated group at the end of the experiment. 
Magnification: 400X. B. Liver weight of the mice in the indicated treatment groups. C. Number of liver nodules in the indicated treatment 
groups. D. Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (Alk Phos) in the 
indicated treatment groups. For B-D, n = 10 in each group. The data represent mean ± SEM. *:p < 0.01. E. Immunohistochemical analysis 
of the indicated proteins in the liver sections of the indicated groups. Arrows indicate microvessels. Magnification: 400X. F. TUNEL 
staining in the liver sections of the indicated groups.
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Figure 2: LSF inhibitors cause G2/M arrest. A. QGY-7703 and Huh7 cells were treated with the indicated concentrations of FQI1 
or FQI2 and cell proliferation was determined by standard MTT assay at the indicated time points. The data represent mean ± SEM. *:p < 
0.01. B. Representative cellular DNA content histograms of the indicated cells treated with 2 μM FQI1 or FQI2. UT indicates untreated or 
vehicle-treated cells. C. Representative cellular DNA content histograms of QGY-7703 cells synchronized by double thymidine block and 
then treated with FQI1 (2 or 5 μM) at the time of release.
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significantly induced upon FQI1 and FQI2 treatment in HCC 
cell lines (Figure 3A). While the level of CDK1 remained 
unchanged, an increase in the mitotic form of CDC25c with 
corresponding decrease in phospho-Ser216-CDC25c was 
observed upon FQI1 and FQI2 treatment (Figure 3A).
The increase in CyclinB1 upon FQI treatment was 
analyzed in more detail using a time-course analysis. Upon 
release of serum-starved cells, CyclinB1 induction was evident 
as early as 3 h after FQI1 treatment in QGY-7703 cells and at 
12 h post-treatment in Huh7 cells with peak induction observed 
at 24 h for QGY-7703 cells and 36 h for Huh7 cells (Figure 3B). 
Immunofluorescence analysis confirmed increased expression 
of CyclinB1 in FQI-treated QGY-7703 cells compared to 
control cells (Supplementary Figure S2). Nuclear translocation 
of CyclinB1 was observed at 12 h of FQI treatment especially 
with FQI2 (Supplementary Figure S2). To determine whether 
the kinetics of increase in Cyclin B1 levels corresponded to the 
normal kinetics at the G
2
/M transition, CyclinB1 expression 
levels were determined in QGY-7703 cells synchronization by 
a double thymidine block and addition of 2 μM or 5 μM FQI1 
at the time of release. At 7 h post-release, both vehicle-treated 
and FQI-treated cells showed an increase in Cyclin B1 levels. 
At 10 h post-treatment, when vehicle-treated cells returned 
to G1 (Figure 2C), CyclinB1 level returned to base-line level, 
as expected. In contrast, the increased level of cyclin B1 was 
sustained in FQI1-treated cells (Figure 3C).
Inhibition of CyclinB1 or CDK1 protects from 
G2/M arrest upon FQI treatment
Since de novo protein synthesis is required for 
CyclinB1 induction at G
2
/M checkpoint we treated the cells 
Figure 3: LSF inhibitors augment CyclinB1 levels. A. Western blot analysis of the indicated proteins in the indicated cells upon 
treatment with 2 μM FQI1 or FQI2 for 24 h. B. Time course analysis of CyclinB1 expression level in the indicated cells upon treatment 
with FQI1 or FQI2. EF1α expression was analyzed as loading control. C. Time course analysis of CyclinB1 expression level in QGY-7703 
cells synchronized by double thymidine block and then treated with FQI1 (2 or 5 μM) at the time of release.
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with protein synthesis inhibitor cycloheximide (CHX; 10 
μg/ml) and performed cell cycle analysis. CHX treatment 
markedly inhibited CyclinB1 induction upon FQI treatment, 
as expected (Figure 4A). Correspondingly a profound 
protection from FQI-induced G
2
/M arrest was observed 
upon CHX treatment (Figure 4B and Supplementary 
Figure S3). Inhibition of CDK activity by treatment with 
a cell-permeable inhibitor Roscovitine (Rosc; 30 μM) 
also abrogated CyclinB1 induction upon FQI treatment 
(Figure 5A) and provided marked protection from G
2
/M 
arrest (Figure 5B and Supplementary Figure S4). These 
findings suggest a key role of CyclinB1/CDK1 in the 
maintenance of G
2
/M arrest upon FQI treatment. The role 
of CyclinB1 was checked by transfecting CyclinB1 siRNA 
and analyzing cell cycle following FQI treatment. CyclinB1 
siRNA provided significant protection from FQI-induced 
cell cycle arrest (Supplementary Figure S5). However, 
the magnitude of the protection was not as robust as that 
provided by CHX or Roscovitine which might be due to 
long kinetics of the assay using the siRNA.
Persistent CyclinB1 overexpression has been 
identified as a marker for recurrent HCC [16]. We, 
therefore analyzed DMSO and FQI-treated tumor samples 
for CyclinB1 expression. While low level CyclinB1 
expression was detected in vehicle-treated tumors, it 
was barely detectable in FQI-treated normal liver tissue 
(Supplementary Figure S6). These findings suggest that 
proliferating tumor cells express low level of CyclinB1. 
In FQI-treated cells, transient high induction of CyclinB1 
in tumor cells leads to cell cycle arrest and eventual death. 
As such at the end of the study CyclinB1 expression is not 
detected in FQI-treated normal liver tissue.
Figure 4: Cycloheximide (CHX) treatment protects HCC cells from FQIs-induced G2/M arrest. A. Western blot analysis 
of CyclinB1 and EF1α in the indicated cells upon 2 h pre-treatment with CHX followed by treatment with FQI1 or FQI2. B. Representative 
cell cycle histograms of the indicated cells upon 2 h pre-treatment with CHX followed by treatment with FQI1 or FQI2.
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LSF inhibitors induce mitotic arrest
The induction of mitotic CDC25c upon FQI 
treatment (Figure 3A) suggests potential mitotic arrest of 
the cells. Staining of DNA in QGY-7703 and Huh7 cells 
with DAPI clearly showed multinucleated cells upon FQI 
treatment, which result from slippage after mitotic arrest 
(Figure 6A, arrows). To capture the bulk of the cells shortly 
after FQI-mediated cell cycle blockage, QGY-7703 cells, 
synchronized by double thymidine block and released in 
the presence of 2 μM FQI1, were harvested at 11 h post-
release. Cells were co-stained for α-tubulin and DNA 
(using DAPI). Most of the cells in the vehicle group have 
already undergone mitosis, although a few were imaged 
still at metaphase or undergoing cytokinesis (Figure 6B). 
In contrast, the FQI-treated cells remained in prometaphase 
with condensed, but not congressed, DNA and spindle that 
were either incomplete or disrupted (the latter indicated 
with arrows) (Figure 6B). At later time-points (48 h), 
multinucleation was also observed in H&E-stained QGY-
7703 cells (Figure 6C). A sustained activation of stress-
activated kinase JNK, but not p38 MAPK, was observed 
when the cells were treated with FQIs (Figure 6D).
LSF inhibitors induce apoptosis
We previously showed that FQI1 treatment of QGY-
7703 leads to apoptosis, as measured by TUNEL staining 
[12]. To further these findings in the context of the mitotic 
phenotypes, we characterized this apoptotic cell death upon 
FQI treatment using a number of other molecular markers. 
In QGY-7703 and Huh7 cells a significant increase in 
Caspase 3 activity was observed upon treatment with 
FQI1 or FQI2 (Figure 7A). Correspondingly, a significant 
increase in apoptotic cells was observed upon Annexin V 
staining followed by flow cytometry (Figure 7B). Cleavage 
of PARP, another marker of apoptosis, was observed in 
these cells when treated with FQI (Figure 7C). Although 
the total level of the anti-apoptotic protein Bcl-xL did not 
change, an increase in phospho-Bcl-xL and a decrease in the 
anti-apoptotic proteins Mcl1 and XIAP were observed in the 
HCC cells upon treatment with LSF inhibitors (Figure 7C).
DISCUSSION
In the present study we report the chemotherapeutic 
efficacy of LSF inhibitors on DEN-induced HCC in 
Alb/c-myc transgenic mice. We previously documented 
that the FQI1 inhibits human HCC xenografts in a nude 
mouse model [12]. Here we document that treatment 
with LSF inhibitors significantly reduced tumor burden 
in Alb/c-myc mice accompanied by a significant decrease 
in serum levels of liver enzymes that are markers of 
liver damage [17]. In addition both FQI1 and FQI2 
significantly inhibited proliferation and angiogenesis 
and caused a significant decrease in the expression of the 
LSF-target gene OPN [5]. These results confirm that FQIs 
maintain their functional attributes, which were initially 
gleaned from in vitro and nude mice studies [12], in an 
immunocompetent endogenous HCC model. It should 
be noted that the treatment with FQIs was initiated at 22 
weeks when tumors have already developed suggesting 
that FQIs caused tumor regression rather than just 
inhibition of growth. Further in vitro assays demonstrate 
that FQIs exert a broad spectrum of anti-cancer effects 
involving mitotic arrest, which significantly bolsters their 
clinical relevance as HCC therapeutics.
The transition of cells from G
2
 to M phase of cell 
cycle is controlled by members of the Cyclin/CDK family 
[18]. The activation of CyclinB1/CDK1 is required for 
progression of cells from G
2
 to M Phase in normal cells 
[19]. The progression of cells to M phase requires stepwise 
activation of CDK1 [20]. CDK1 can be deactivated by 
phosphorylation at Thr14 and Tyr15 by Wee1 and Myt1 
[21, 22]. Cdc25C is a phosphatase that dephosphorylates 
Thr14 and Tyr15 of CDK1. Cdc25C can be inactivated 
by phosphorylation at Ser216 by Chk1 and subsequent 
sequestration of Cdc25C in the cytoplasm by binding of 
Chk2 with members of the 14-3-3 protein family prevents 
premature mitosis [23]. Many cytotoxic compounds 
and DNA damaging agents are known to arrest cells in 
different stages of the cell cycle and prevent proliferation 
of cancer cells. These compounds often either deregulate 
or inhibit the activation of Cyclin/CDKs resulting in cell 
cycle arrest. We demonstrate that treatment with LSF 
inhibitors induced a pronounced G
2
/M phase arrest with 
a significant increase in CyclinB1. We also observed 
an increase in the activity of Cdc25c phosphatase and 
decreased levels of p-Ser216-Cdc25C which is an inactive 
form of Cdc25c. This will in turn activate CDK1 leading 
to activation of CyclinB1/CDK1 complex. Our results 
therefore suggest that LSF inhibitors induce G
2
/M phase 
cell cycle arrest, consistent with sustained activity of the 
CyclinB1/CDK1 complex.
To check whether upregulation of CyclinB1/CDK1 
complex is symptomatic of FQI-mediated mitotic blockage 
and apoptosis, we inhibited cell cycle progression with 
either roscovitine or cycloheximide. Treatment with 
Roscovitine, a synthetic CDK inhibitor, has been shown to 
induce a partial G
2
 cell cycle arrest in MCF7 cells [24, 25]. 
We document that treatment with Roscovitine along with 
LSF inhibitors greatly inhibited FQI-induced upregulation 
of CyclinB1 expression. Flow cytometric analysis showed 
that there was slight accumulation of cells in the G
2
/M 
phase in Roscovitine-treated cells when compared to 
control cells. However, Roscovitine plus FQI1 treatment 
resulted in the same amount of G2/M phase cells, therefore 
indicating that Roscovitine inhibited the mitotic defect 
caused by FQI. Treatment with CHX prevented Cyclin 
B1 induction, as expected, and also prevented the FQI-
mediated G
2
/M phase defects. These results indicate that 
induction of G
2
/M phase arrest by LSF inhibitor, which 
is marked by upregulation of CyclinB1/CDK1 activity, 
requires cell cycle progression into mitosis.
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Prolonged activation of CyclinB1/CDK1 during 
mitotic arrest activity leads to phosphorylation of 
numerous apoptotic regulatory proteins such as Mcl1, 
Bcl-2, Bcl-xL, Caspase-9, Caspase-8, and stabilization of 
survivin and/or maintenance of XIAP expression [26, 27]. 
Our results show that mitotic arrest upon treatment with 
LSF inhibitors leads to sustained elevation of CyclinB1/
CDK1, with increased phosphorylation and degradation 
of Mcl1 and Bcl-xL. The activity of JNK was also 
increased which might mediate hyperphosphorylation 
and degradation of Mcl1. Furthermore, XIAP expression 
was decreased upon LSF inhibitor treatment. Proapoptotic 
indicators, such as increased Caspase-3 activity and PARP 
cleavage, were also observed. These findings provide a 
mechanistic basis for why cells undergo apoptosis after 
prolonged mitotic arrest induced by LSF inhibitors.
In summary, we document that the FQI family of 
LSF inhibitors have multiple consequences. On one hand, 
as previously shown, inhibition of LSF transcriptional 
activity blocks induction of LSF target genes that mediate 
downstream oncogenic signaling. Additionally, these 
inhibitors cause mitotic arrest culminating into apoptosis. 
These multiple targets exert profound anti-cancer activity 
which is confirmed by marked reduction in tumor burden 
in DEN-treated Alb/c-myc mice. The mechanism by 
which LSF inhibitors induce mitotic arrest remains 
to be fully elucidated, and is a focus of current efforts. 
Lack of toxicity combined with multimodal anti-cancer 
mechanisms support the hypothesis that LSF inhibitors 
may prove to be clinically relevant and potentially 
effective therapeutics for HCC. Since LSF promotes 
both primary tumors and metastasis FQIs might be useful 
for treating advanced metastatic HCC either alone or in 
combination with receptor tyrosine kinase inhibitors, such 
as sorafenib, thereby providing dual pronged attack for 
successful elimination of the disease.
Figure 5: Inhibition of CDK1 protects HCC cells from FQIs-induced G2/M arrest. A. Western blot analysis of CyclinB1 and 
EF1α in the indicated cells upon 2 h pre-treatment with Roscovitine (Rosc) followed by treatment with FQI1 or FQI2. B. Representative 
cell cycle histograms of the indicated cells upon 2 h pre-treatment with Roscovitine (Rosc) followed by treatment with FQI1 or FQI2.
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MATERIALS AND METHODS
Chemicals
Small molecule inhibitors of LSF, FQI1 and its 
achiral analogue FQI2, have been described previously 
[12]. After initial titration, in vitro assays were performed 
using either 2 or 5 μM FQI1 or FQI2. As indicated, cells 
were pre-treated for 2 h with Cycloheximide (10 μg/ml; 
Sigma; C7698) or Roscovitine (30 μM; Cell Signaling; 
#9885) before treatment with LSF inhibitors. Control and 
Cyclin B1 siRNAs were obtained from Santa Cruz Biotech 
(sc-37007 and sc-29284, respectively).
Animal studies
The generation and characterization of Alb/c-myc 
mouse have been described previously [13]. These mice 
were kindly provided by Dr. Snorri S. Thorgeirsson (NIH/
NCI). Wild-type mice were bred with heterozygous Alb/c-
myc mice to obtain the experimental cohort of animals. 
For induction of chemical carcinogenesis, a single 
intraperitoneal (i.p.) injection of 10 μg/gm body weight 
of N-nitrosodiethylamine (DEN) was given at 14 days 
of age to male Alb/c-myc mice [13]. The animals were 
divided randomly into 3 groups (10 mice per group) and 
treated with i.p. injections of FQI1 or FQI2 (4 mg/kg). 
The treatment started at 22 weeks of age with 3 cycles 
of treatment (5 injections per week per cycle) over 6 
weeks and the animals were sacrificed 2 weeks after the 
last injection. Blood samples were collected for liver 
enzyme analysis at the Molecular Diagnostic Laboratory, 
Department of Pathology, Virginia Commonwealth 
University. The liver tissue was fixed in 10% formalin and 
used for histopathology and immunohistochemistry studies.
Cells, culture condition, cell cycle and apoptosis 
assays
Human HCC cells, QGY-7703 and Huh7, were 
cultured as previously described [12, 28]. Cell proliferation 
was determined by standard MTT assays as described [12, 
28]. In initial experiments, HCC cells were synchronized by 
culturing in growth medium containing 0.5% FBS for 48 h, 
Figure 6: FQIs induce mitotic arrest. QGY-7703 cells were treated for 12 h while Huh7 cells were treated for 24 h 
with FQIs. A. Representative photomicrographs of DAPI-stained cells. Arrows indicate multinucleated cells. B. QGY-7703 cells were 
synchronized by double thymidine block and then released in the presence of 2 μM FQI1. Cells harvested at 11 h post-release were stained 
for α-tubulin and DNA (using DAPI). Representative images taken at 63x magnification are shown. C. QGY-7703 cells were treated as in B 
except with 5 μM FQI1. Cells were stained with Hematoxylin and Eosin 48 h post-release. D. Western blot analysis of the indicated proteins 
in the indicated cells upon treatment with FQI1 or FQI2. QGY-7703 cells were treated for 24 h.
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followed by FQI1 or FQI2 treatment in complete growth 
medium containing 10% FBS. For Cycloheximide and/
or Roscovitine experiments, serum-starved synchronized 
cells were pretreated with respective agents for 2 h in 
complete growth medium prior to FQI1 or FQI2 treatment. 
Additionally, cell cycle synchronization of QGY-7703 
cells was achieved by double thymidine block essentially 
as described previously [29], followed by release at 0 h in 
the presence of FQI1. At the end of the experiment cells 
were harvested, fixed in 70% ethanol and stained with 
propidium iodide followed by flow cytometry for cell cycle 
analysis [30]. For siRNA experiments, QGY-7703 cells 
were synchronized by serum starvation for 24 h following 
which siRNAs were transfected. After 24 h, the cells were 
again synchronized by overnight serum starvation, treated 
with FQI1 or FQI2 for 24 h and cell cycle was analyzed. 
Apoptosis was determined by annexin V-binding assay 
followed by flow cytometry as described [31]. The activity 
of Caspase-3 was assessed by the EnzChek caspase-3 assay 
kit from Molecular Probes using the manufacturer’s protocol.
Preparation of whole cell lysates and western 
blot analyses
Preparation of whole-cell lysates and Western blot 
analyses were performed as described [28]. The primary 
antibodies used were anti-CyclinB1 (1:1,000, rabbit 
polyclonal; Cell Signaling), anti-Cyclin B1 (1:1000, mouse 
Figure 7: LSF inhibitors induce apoptosis. A. Caspase 3 activity (mM of AMC released/ mg protein/ 30 min) was measured in the 
indicated cells upon treatment with 2 μM FQI1 or FQI2. QGY-7703 cells were treated for 24 h. The data represent mean ± SEM. *:p < 0.01. 
B. Apoptosis was measured by Annexin V staining followed by flow cytometry in the indicated cells upon treatment with 2 μM FQI1 or 
FQI2. QGY-7703 cells were treated for 24 h. The data represent mean ± SEM. *:p < 0.01. C. Western blot analysis of the indicated proteins 
in the indicated cells upon treatment with FQI1 or FQI2 for the indicated periods of time.
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monoclonal [V152]; Abcam), anti-CDK1 (1:1, 000, rabbit 
polyclonal; Cell Signaling), anti-pSer216-CDC25c (1:1,000, 
rabbit monoclonal; Cell Signaling), anti-CDC25c (1:1,000, 
rabbit monoclonal; Cell Signaling), anti-p-JNK (1:1,000, 
rabbit monoclonal; Cell Signaling), anti-JNK (1:1,000, 
rabbit polyclonal; Cell Signaling), anti-p-p38 MAPK 
(1:1,000, rabbit monoclonal; Cell Signaling), anti-p38 
MAPK (1:1,000, rabbit monoclonal; Cell Signaling), anti-
p-Bcl-xL (1:1,000, rabbit polyclonal; Thermo Scientific), 
anti-Bcl-xL (1:1,000, rabbit monoclonal; Cell Signaling), 
anti-Mcl1 (1:1,000, rabbit monoclonal; Cell Signaling), 
anti-XIAP (1:1,000, rabbit polyclonal; Cell Signaling) and 
anti-PARP (1:1,000, rabbit polyclonal; Cell Signaling). 
Blots were stripped and normalized by reprobing with anti-
EF1α (1:2,000, mouse monoclonal; Millipore) and β-actin 
(1:20,000, mouse monoclonal; Sigma).
Immunohistochemistry
Immunohistochemistry was carried out using formalin-
fixed paraffin-embedded (FFPE) sections as described [28]. 
The sections were blocked in phosphate buffered saline-
tween 20 (PBST) using 10% normal goat serum. The 
primary antibodies were diluted in PBST containing 5% 
goat serum. The primary antibodies used were: anti-AFP 
(Santa Cruz; rabbit polyclonal; 1:50); anti-CD31 (Dako; 
mouse monoclonal; 1:50); anti-PCNA (Cell Signaling; 
mouse monoclonal; 1:100); anti-OPN (Millipore; rabbit 
polyclonal; 1:500); anti-CyclinB1 (1:100, rabbit polyclonal; 
Cell Signaling). Secondary antibodies were diluted in PBST 
containing corresponding 2.5% blocking serum. The signals 
were developed by avidin-biotin-peroxidase complexes with 
a DAB substrate solution (Vector laboratories). Images were 
analyzed using an Olympus microscope.
Immunofluorescence
Immunofluorescence was performed as described 
[28]. The primary antibody was anti-α-Tubulin (Cell 
Signaling; mouse monoclonal; 1:2000) and the secondary 
antibody was Alexa488-conjugated anti-mouse IgG 
(Molecular Probes; 1:500). The slides were mounted in 
VectaShield fluorescence mounting medium containing 
4, 6-diamidino-2-phenylindole (Vector Laboratories). 
Images were analyzed using a Zeiss confocal laser scanning 
microscope. Alternatively, cells were stained with α-tubulin 
antibody (1:50, mouse monoclonal; Abcam) followed by 
a CY5-conjugated secondary anti-mouse antibody (1:200; 
Abcam). The cover slips were mounted with Invitrogen Anti 
Fade Mounting Medium containing DAPI and imaged using 
a Zeiss AxioImager.Z1 microscope at 63x magnification.
Immunocytochemistry
QGY-7703 cells synchronized with a double thymidine 
block were released in the presence of 5 μM FQI1. Forty-eight 
hours after release, cells were harvested, fixed, and stained 
using Hematoxylin and Eosin. Images were captured using 
a Zeiss AxioImager. Z1 microscope at 100x magnification.
Statistical analysis
Data were represented as the mean ± Standard Error 
of Mean (S.E.M) and analyzed for statistical significance 
using one-way analysis of variance (ANOVA) followed by 
Newman-Keuls test as a post hoc test. A P value of < 0.05 
was considered as significant.
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